Immunosuppressants drugs for COVID-19: living meta-analysis of clinical studies

Table Graph

Immunosuppressants drugs - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.76 [0.67, 0.87]	< 1	7%	26 studies (26/-)	100.0 %	some concern	critical	moderate	crucial	-
death or transfer to ICU	0.66 [0.32, 1.37]	< 1	76%	3 studies (1/2)	87.0 %	low	not evaluable	high	crucial	-
deaths	0.71 [0.64, 0.78]	< 1	25%	57 studies (41/16)	100.0 %	moderate	critical	moderate	crucial	-
deaths (time to event analysis only)	0.71 [0.57, 0.88]	< 1	46%	11 studies (7/4)	99.9 %	moderate	low	moderate	crucial	-
clinical deterioration	0.71 [0.52, 0.98]	< 1	61%	10 studies (10/-)	98.2 %	some concern	critical	moderate	important	-
clinical improvement	1.24 [1.13, 1.37]	> 1	18%	13 studies (13/-)	100.0 %	low	critical	high	important	-
clinical improvement (14-day)	1.38 [1.17, 1.62]	> 1	14%	4 studies (4/-)	100.0 %	low	not evaluable	high	important	-
clinical improvement (28-day)	1.33 [0.95, 1.87]	> 1	0%	4 studies (4/-)	95.3 %	some concern	not evaluable	moderate	important	-
clinical improvement (time to event analysis only)	1.14 [1.03, 1.27]	> 1	0%	4 studies (4/-)	99.4 %	low	not evaluable	high	important	-
death or ventilation	0.83 [0.77, 0.91]	< 1	18%	13 studies (13/-)	100.0 %	some concern	low	moderate	important	-
hospital discharge	2.63 [0.99, 7.00]	> 1	97%	3 studies (2/1)	97.3 %	serious	not evaluable	low	important	-
mechanical ventilation	0.79 [0.65, 0.96]	< 1	14%	10 studies (10/-)	99.0 %	some concern	low	moderate	important	-
ICU admission	0.47 [0.21, 1.07]	< 1	78%	8 studies (4/4)	96.4 %	moderate	not evaluable	moderate	non important	-
recovery	1.30 [0.64, 2.66]	> 1	9%	2 studies (2/-)	76.5 %	low	not evaluable	high	non important	-
safety endpoints 00
related AE (TRAE)	1.26 [0.14, 11.07]	< 1	0%	2 studies (2/-)	41.9 %	some concern	not evaluable	moderate	important	-
serious adverse events	0.94 [0.78, 1.13]	< 1	0%	10 studies (10/-)	74.7 %	some concern	critical	moderate	important	-
superinfection	1.26 [0.20, 7.90]	< 1	95%	2 studies (1/1)	40.4 %	moderate	not evaluable	moderate	important	-
acute kidney injury	0.43 [0.14, 1.34]	< 1	0%	1 study (-/1)	92.7 %	NA	not evaluable		non important	-
adverse events	1.32 [0.92, 1.91]	< 1	57%	9 studies (9/-)	6.7 %	some concern	not evaluable	moderate	non important	-
arrhythmia	0.16 [0.03, 0.90]	< 1	0%	1 study (-/1)	98.1 %	NA	not evaluable		non important	-
elevated liver enzymes	0.52 [0.18, 1.51]	< 1	0%	1 study (-/1)	88.5 %	NA	not evaluable		non important	-
Myocardial infarction	0.87 [0.19, 3.92]	< 1	0%	1 study (-/1)	57.2 %	NA	not evaluable		non important	-
venous thromboembolism	5.23 [0.42, 65.62]	< 1	0%	1 study (-/1)	10.2 %	NA	not evaluable		non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

Immunosuppressants drugs - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00